Alnylam Pharmaceuticals (NASDAQ:ALNY) Lowered to “Hold” at StockNews.com

StockNews.com downgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from a buy rating to a hold rating in a research note issued to investors on Sunday.

ALNY has been the topic of several other research reports. Morgan Stanley reduced their price objective on Alnylam Pharmaceuticals from $184.00 to $176.00 and set an equal weight rating on the stock in a report on Tuesday, February 13th. JPMorgan Chase & Co. upped their price objective on Alnylam Pharmaceuticals from $150.00 to $170.00 and gave the stock a neutral rating in a report on Thursday, February 1st. Royal Bank of Canada reaffirmed an outperform rating and set a $235.00 price objective on shares of Alnylam Pharmaceuticals in a report on Tuesday, February 20th. Needham & Company LLC reaffirmed a buy rating and set a $200.00 price objective on shares of Alnylam Pharmaceuticals in a report on Thursday, February 15th. Finally, Wolfe Research started coverage on Alnylam Pharmaceuticals in a report on Thursday, February 15th. They set a peer perform rating on the stock. Nine equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of Moderate Buy and an average target price of $216.12.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY opened at $144.41 on Friday. The company has a market capitalization of $18.19 billion, a P/E ratio of -40.56 and a beta of 0.39. Alnylam Pharmaceuticals has a one year low of $143.50 and a one year high of $218.88. The business’s 50 day simple moving average is $151.56 and its 200-day simple moving average is $166.73.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.10) EPS for the quarter, topping the consensus estimate of ($1.20) by $0.10. The business had revenue of $439.72 million during the quarter, compared to analyst estimates of $439.38 million. The firm’s revenue was up 31.2% compared to the same quarter last year. During the same period in the previous year, the firm earned ($1.68) earnings per share. On average, sell-side analysts anticipate that Alnylam Pharmaceuticals will post -4.54 EPS for the current fiscal year.

Institutional Trading of Alnylam Pharmaceuticals

Large investors have recently made changes to their positions in the company. Allspring Global Investments Holdings LLC increased its position in shares of Alnylam Pharmaceuticals by 572.0% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 143 shares in the last quarter. Quent Capital LLC increased its position in shares of Alnylam Pharmaceuticals by 246.0% in the 4th quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 123 shares in the last quarter. KB Financial Partners LLC bought a new stake in shares of Alnylam Pharmaceuticals in the 1st quarter valued at $35,000. Anchor Investment Management LLC bought a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter valued at $38,000. Finally, Robeco Institutional Asset Management B.V. increased its holdings in Alnylam Pharmaceuticals by 155.7% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 12,513 shares in the last quarter. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.